Objective: To evaluate the efficacy and adverse events of fezolinetant for treating vasomotor symptoms (VMS) of menopause.
This updated version of The British Menopause Society and Women’s Health Concern recommendations on HRT evaluates the evidence on the role of HRT in managing menopausal symptoms as well as that of alternative therapies. It also reviews the effects of HRT on bone, cardiovascular and cognitive function.
Real-world studies based on TVT Registry data demonstrated continued excellent outcomes for patients treated with the Edwards Sapien valve platform
The FDA has granted accelerated approval to zanubrutinib (Brukinsa) in combination with obinutuzumab (Gazyva) for patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy
Avidity Biosciences, Inc. a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), announced new positive long-term AOC 1001 data from the MARINA open-label extension (MARINA-OLE ) trial showing reversal of disease progression in people living with myotonic dystrophy type 1 (DM1) across multiple endpoints including vHOT, muscle strength and activities of daily living when compared to END-DM1 natural history data
Saranas, Inc. announced the compelling results of SAFE-MCS, a multi-center clinical study evaluating the safety of complex high-risk percutaneous coronary intervention (PCI) using mechanical circulatory support (MCS) and surveillance with the Early Bird Bleed Monitoring System (EBBMS)
Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name Prevnar 20, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age
AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases
UCB announced a strategic equity investment in IMIDomics, Inc, a private company dedicated to the advancement of novel medicines for immune-mediated inflammatory diseases (IMIDs)
Vanda Pharmaceuticals Inc. announced that on March 4, 2024, it received a Complete Response Letter (CRL) from the FDA as part of its ongoing review of Vanda's supplemental New Drug Application (sNDA) for Hetlioz (tasimelteon) in the treatment of insomnia characterized by difficulties with sleep initiation